Advertisement
Screener

Neogen Corporation (NEOG) Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities

2.8 / 5 stars · 68/120 Roast Me

Neogen Corporation Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities

Neogen Corporation (NEOG) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $16.29 million for the 12-month period ending 2022-05-31, per its 10-K filed 2022-07-27.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2022-07-27

  • Neogen Corporation increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2021-08-31 was -$2.38M.
  • Neogen Corporation increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2020-08-31 was -$3.11M, a 182.79% decline year-over-year.
  • Neogen Corporation increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2019-08-31 was $3.76M.
  • Neogen Corporation increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $16.29M, a 15265.09% increase from fiscal 2021.
  • Neogen Corporation increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2021 was $106.00K, a 98.51% decline from fiscal 2020.
  • Neogen Corporation increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2020 was $7.10M.
  • Neogen Corporation increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2019 was -$1.21M.
Period endIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 monthIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 monthIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed
2022-05-31$16.29M
10-K · filed 2022-07-27
2021-08-31-$2.38M
10-Q · filed 2021-09-30
2021-05-31$106.00K
10-K · filed 2022-07-27
2020-08-31-$3.11M
10-Q · filed 2021-09-30
2020-05-31$7.10M
10-K · filed 2022-07-27
2019-08-31$3.76M
10-Q · filed 2020-09-30
2019-05-31-$1.21M
10-K · filed 2021-07-30
2018-05-31-$2.28M
10-K · filed 2020-07-30
2017-05-31$3.38M
10-K · filed 2019-07-30
2016-05-31$744.00K
10-K · filed 2018-07-27
$385.00K
10-K · filed 2016-07-29
2015-05-31$353.00K
10-K · filed 2017-07-28
2014-05-31$885.00K
10-K · filed 2016-07-29
2013-05-31-$451.00K
10-K · filed 2015-07-30
2012-05-31-$1.78M
10-K · filed 2014-07-30
-$1.91M
10-K · filed 2012-07-30
2011-05-31-$1.14M
10-K · filed 2013-07-30
-$1.18M
10-K · filed 2012-07-30
2010-05-31$3.48M
10-K · filed 2012-07-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Celldex Therapeutics, Inc. (CLDX)United States$2.471B-9.72
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93